Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | BHMT | Q93088 | 1/20 | 0.40 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15984957 | 1.00 | SLC7A5 (0.46) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| SCHEMBL12434857 | 1.00 | SLC7A5 (0.46) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| SCHEMBL13176779 | 0.88 | GABRR1 (0.39) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| SCHEMBL16118377 | 0.88 | NOS2 (0.46) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| Cystine SCHEMBL28213243 | 0.86 | SLC7A5 (0.50) | SLC7A5NOS2NOS1NOS3SLC1A3 | |
| SCHEMBL16626924 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| SCHEMBL11193240 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| SCHEMBL6537085 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| SCHEMBL5518553 | 0.86 | GABRR1 (0.46) | GABRR1ENPEP | |
| Cystine SCHEMBL8332353 | 0.86 | PTGS1 (0.50) | SLC7A5NOS2NOS1NOS3SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173947-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| US-8835599-B2 | Segmented degradable polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-8815227-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8440787-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130072709-A1 | Segmented Degradable Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2013-03-21 | — | — | US | disclosed |
| US-8309680-B2 | Segmented degradable polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100286355-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100010158-A1 | Segmented Degradable Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | SLC7A5 1076/4885NOS2 4319/4885NOS1 4447/4885 |
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, FGF23, PTH1R | SLC7A5 648/4885NOS2 2619/4885NOS1 3384/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | SLC7A5 1091/4885NOS2 4670/4885NOS1 4728/4885 |
| US-20130072709-A1 | Segmented Degradable Polymers and Conjugates Made Therefrom | SI, PLG, LGMN | SLC7A5 547/4885NOS2 1523/4885NOS1 2399/4885 |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | SLC7A5 1076/4885NOS2 4319/4885NOS1 4447/4885 |
| US-20100286355-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, HAAO, FGF23 | SLC7A5 430/4885NOS2 4175/4885NOS1 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.